newsfilter
← Latest News
GlobeNewswire·

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day

AXSM
  • The "Shared Goals: Navigating Alzheimer's Agitation" survey conducted by The Harris Poll for Axsome Therapeutics & CaringKind reveals that 97% of care partners reported agitation negatively impacted their loved one's quality of life.
  • 76% of care partners wished they had recognized agitation symptoms sooner, while 53% regretted not discussing these symptoms with healthcare providers earlier.
  • Survey results were presented at Psych Congress 2026 in New Orleans, Louisiana, on September 17-18, 2026, highlighting that agitation is often misidentified as personality changes or disease progression.
  • 96% of respondents noted agitation affected their loved one's ability to care for themselves, 95% cited impacts on community engagement, & 89% reported damage to family & friend relationships.
  • Nonaggressive symptoms were identified as most detrimental, including complaining or frequent requests for help (76%), repetitive sentences or inappropriate laughter/crying (75%), repetitive mannerisms (67%), & pacing or aimless wandering (56%).
  • 89% of care partners expressed a desire for easier ways to track agitation symptoms over time, & 81% wanted tools to discreetly share symptom data with doctors.
  • 47% of caregivers expressed worry regarding medication decisions, while 93% wished for a medication that reduces agitation without causing negative side effects.
  • The online survey included 751 U.S. adults providing informal care to a loved one with Alzheimer's disease, conducted between October 7-28, 2025.
  • Agitation affects up to 75% of Alzheimer's patients, is linked to accelerated cognitive decline, increased caregiver burden, & is a leading cause of nursing home placement.
  • Axsome Therapeutics sponsors the survey & maintains FDA-approved treatments for agitation associated with dementia due to Alzheimer's disease among its CNS disorder portfolio.